Zhao Qi, Peng Xiao-Yan, Chen Feng-Hua, Zhang Yong-Peng, Wang Lian, You Qi-Sheng, Jonas Jost B
Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Lab, Beijing, ChinaDepartment of Ophthalmology, Puren Hospital of Beijing, Beijing, ChinaDepartment of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Lab, Beijing, ChinaDepartment of Ophthalmology, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Mannheim, Germany.
Acta Ophthalmol. 2014 May;92(3):e225-8. doi: 10.1111/aos.12158. Epub 2013 Jun 13.
To examine whether vascular endothelial growth factor (VEGF) as one of the most important intraocular cytokines for angiogenesis and increased vascular permeability is associated with Coats' disease.
The clinical interventional study included 28 patients with Coats' disease and seven control patients with congenital cataract. During intraocular surgery, we obtained aqueous humour samples in which the VEGF concentration was measured by double-antibody sandwich enzyme-linked immunosorbent assay (ELISA). Coats' disease was graded into four stages.
The mean aqueous VEGF level was significantly higher in the Coats' study group than in the control group (158±88 versus 97±21 pg/ml; p=0.002). The VEGF concentrations increased significantly (p<0.001) from 91±32 pg/ml in Coats' disease stage 2 to 100±37 pg/ml in stage 3A1, 185±56 pg/ml in stage 3A2 to 256±93 pg/ml in patients with stage 3B. Vascular endothelial growth factor concentrations in Coats' stage 2 and 3A1 did not differ significantly from the values in the control group. Parallel to the association with the stage of the diseases, the VEGF concentrations were significantly (p<0.001) correlated with extent of exudative retinal detachment.
Increasing severity of Coats' disease is significantly associated with intraocular VEGF concentrations. These results favour the intravitreal application of anti-VEGF drugs as medical therapy of Coats' diseases.
研究血管内皮生长因子（VEGF）作为眼内最重要的促血管生成和增加血管通透性的细胞因子之一，是否与科茨病相关。
临床干预研究纳入了28例科茨病患者和7例先天性白内障对照患者。在眼科手术期间，我们采集了房水样本，采用双抗体夹心酶联免疫吸附测定（ELISA）法测定其中的VEGF浓度。科茨病分为四个阶段。
科茨病研究组的房水VEGF平均水平显著高于对照组（158±88对97±21 pg/ml；p = 0.002）。VEGF浓度从科茨病2期的91±32 pg/ml显著增加（p < 0.001）至3A1期的100±37 pg/ml、3A2期的185±56 pg/ml，再到3B期患者的256±93 pg/ml。科茨病2期和3A1期的血管内皮生长因子浓度与对照组的值无显著差异。与疾病阶段的关联相似，VEGF浓度与渗出性视网膜脱离的范围显著相关（p < 0.001）。
科茨病严重程度的增加与眼内VEGF浓度显著相关。这些结果支持将抗VEGF药物玻璃体内注射作为科茨病的药物治疗方法。
